Floatz logo

Cobomarsen

Diffuse Large B-Cell Lymphoma Activated B-Cell Type

miRagen Therapeutics, Inc.nucleic_acidPhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Diffuse Large B-Cell Lymphoma Activated B-Cell Type cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2/3BB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2/3BB
Inno-206
National Cancer Institute (NCI)
Phase 2/3BB

View all 20 →

Same molecule, other indications

Cobomarsen is also rated in:

mycosis fungoidesDormant
CC
Indicative ·
46 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
C
Indicative ·
38 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →